The current financial score of Novocure Ltd is 6.87. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 183.58M, representing a year-over-year increase of 15.60%, while its net profit experienced a year-over-year increase of 60.99%.
The current valuation score of Novocure Ltd is 9.06. Its current P/E ratio is -10.88, which is -45.05% below the recent high of -5.98 and -1135.16% above the recent low of -134.38.
The current earnings forecast score of Novocure Ltd is 7.43. The average price target is 28.83, with a high of 52.00 and a low of 20.00.
The current price momentum score of Novocure Ltd is 5.06. Currently, the stock price is trading between the resistance level at 18.49 and the support level at 15.00, making it suitable for range-bound swing trading.
The current institutional shareholding score of Novocure Ltd is 7.00. The latest institutional shareholding proportion is 85.75%, representing a quarter-over-quarter increase of 1.87%. The largest institutional shareholder is James Simons, holding a total of 1.95M shares, representing 0.04% of shares outstanding, with 96.43% increase in holdings.
The current risk assessment score of Novocure Ltd is 4.86. The company's beta value is 0.93. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.